These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 15890583)

  • 1. Individualized planning target volumes for intrafraction motion during hypofractionated intensity-modulated radiotherapy boost for prostate cancer.
    Cheung P; Sixel K; Morton G; Loblaw DA; Tirona R; Pang G; Choo R; Szumacher E; Deboer G; Pignol JP
    Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):418-25. PubMed ID: 15890583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term results of a study using individualized planning target volumes for hypofractionated intensity-modulated radiotherapy boost for prostate cancer.
    Chu W; Loblaw DA; Chan K; Morton G; Choo R; Szumacher E; Danjoux C; Pignol JP; Cheung P
    Radiat Oncol; 2015 Apr; 10():95. PubMed ID: 25903934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate and patient intrafraction motion: impact on treatment time-dependent planning margins for patients with endorectal balloon.
    Steiner E; Georg D; Goldner G; Stock M
    Int J Radiat Oncol Biol Phys; 2013 Jul; 86(4):755-61. PubMed ID: 23582854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a simultaneous boost IMRT class solution for a hypofractionated prostate cancer protocol.
    Mott JH; Livsey JE; Logue JP
    Br J Radiol; 2004 May; 77(917):377-86. PubMed ID: 15121701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase II trial of arc-based hypofractionated intensity-modulated radiotherapy in localized prostate cancer.
    Lock M; Best L; Wong E; Bauman G; D'Souza D; Venkatesan V; Sexton T; Ahmad B; Izawa J; Rodrigues G
    Int J Radiat Oncol Biol Phys; 2011 Aug; 80(5):1306-15. PubMed ID: 20708855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical application of high-dose, image-guided intensity-modulated radiotherapy in high-risk prostate cancer.
    Bayley A; Rosewall T; Craig T; Bristow R; Chung P; Gospodarowicz M; Ménard C; Milosevic M; Warde P; Catton C
    Int J Radiat Oncol Biol Phys; 2010 Jun; 77(2):477-83. PubMed ID: 19733014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toxicity assessment of pelvic intensity-modulated radiotherapy with hypofractionated simultaneous integrated boost to prostate for intermediate- and high-risk prostate cancer.
    McCammon R; Rusthoven KE; Kavanagh B; Newell S; Newman F; Raben D
    Int J Radiat Oncol Biol Phys; 2009 Oct; 75(2):413-20. PubMed ID: 19362783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the dosimetric impact of non-exclusion of the rectum from the boost PTV in IMRT treatment plans for prostate cancer patients.
    Kassim I; Dirkx ML; Heijmen BJ
    Radiother Oncol; 2009 Jul; 92(1):62-7. PubMed ID: 19278745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Image-guided intensity-modulated radiotherapy of prostate cancer: Analysis of interfractional errors and acute toxicity.
    Rudat V; Nour A; Hammoud M; Alaradi A; Mohammed A
    Strahlenther Onkol; 2016 Feb; 192(2):109-17. PubMed ID: 26545764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Online image-guided intensity-modulated radiotherapy for prostate cancer: How much improvement can we expect? A theoretical assessment of clinical benefits and potential dose escalation by improving precision and accuracy of radiation delivery.
    Ghilezan M; Yan D; Liang J; Jaffray D; Wong J; Martinez A
    Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1602-10. PubMed ID: 15590192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypofractionated accelerated radiotherapy using concomitant intensity-modulated radiotherapy boost technique for localized high-risk prostate cancer: acute toxicity results.
    Lim TS; Cheung PC; Loblaw DA; Morton G; Sixel KE; Pang G; Basran P; Zhang L; Tirona R; Szumacher E; Danjoux C; Choo R; Thomas G
    Int J Radiat Oncol Biol Phys; 2008 Sep; 72(1):85-92. PubMed ID: 18355982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A dose-escalation trial with the adaptive radiotherapy process as a delivery system in localized prostate cancer: analysis of chronic toxicity.
    Brabbins D; Martinez A; Yan D; Lockman D; Wallace M; Gustafson G; Chen P; Vicini F; Wong J
    Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):400-8. PubMed ID: 15667959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pelvic nodal dose escalation with prostate hypofractionation using conformal avoidance defined (H-CAD) intensity modulated radiation therapy.
    Hong TS; Tomé WA; Jaradat H; Raisbeck BM; Ritter MA
    Acta Oncol; 2006; 45(6):717-27. PubMed ID: 16938815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dosimetric implications of residual seminal vesicle motion in fiducial-guided intensity-modulated radiotherapy for prostate cancer.
    Stenmark MH; Vineberg K; Ten Haken RK; Hamstra DA; Feng M
    Med Dosim; 2012; 37(3):240-4. PubMed ID: 22189029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short-course intensity-modulated radiotherapy for localized prostate cancer with daily transabdominal ultrasound localization of the prostate gland.
    Mohan DS; Kupelian PA; Willoughby TR
    Int J Radiat Oncol Biol Phys; 2000 Feb; 46(3):575-80. PubMed ID: 10701736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypofractionated intensity-modulated arc therapy for lymph node metastasized prostate cancer.
    Fonteyne V; De Gersem W; De Neve W; Jacobs F; Lumen N; Vandecasteele K; Villeirs G; De Meerleer G
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1013-20. PubMed ID: 19386427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of antiflatulent dietary advice on intrafraction motion for prostate cancer radiotherapy.
    Lips IM; Kotte AN; van Gils CH; van Leerdam ME; van der Heide UA; van Vulpen M
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e401-6. PubMed ID: 21664067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toxicity after three-dimensional radiotherapy for prostate cancer with RTOG 9406 dose level IV.
    Michalski JM; Winter K; Purdy JA; Perez CA; Ryu JK; Parliament MB; Valicenti RK; Roach M; Sandler HM; Markoe AM; Cox JD
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):735-42. PubMed ID: 14967428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of inter- and intrafraction deviations and residual set-up errors on PTV margins. Different alignment techniques in 3D conformal prostate cancer radiotherapy.
    Langsenlehner T; Döller C; Winkler P; Gallé G; Kapp KS
    Strahlenther Onkol; 2013 Apr; 189(4):321-8. PubMed ID: 23443612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.